Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY22 results · Jul–Sep 2021

Strides Pharma Science reported revenue from operations of ₹721.47 crore (down 9.1% from Q2 FY21) and net loss of ₹167.98 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	721.47	793.56	−9.1%	688.37	+4.8%
Other income	22.21	12.87	+72.6%	13.53	+64.1%
Total income	743.68	806.43	−7.8%	701.90	+6.0%
Profit before share of associates & JVs and tax	(151.37)	98.44	Turned loss	(224.58)	Loss narrowed
Share of profit/(loss) of associates & JVs	(23.37)	(30.12)		(19.53)
Net profit for the period	(167.98)	76.99	Turned loss	(208.57)	Loss narrowed
Attributable to shareholders of the company	(162.56)	80.94	Turned loss	(205.20)	Loss narrowed
EPS, basic (₹)	(18.12)	9.03	Turned loss	(22.88)	Loss narrowed
Net margin (%)	-23.3	9.7		-30.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	575.00	384.33	+49.6%	508.79	+13.0%
Other income	22.41	38.54	−41.8%	8.75	+156.2%
Total income	597.41	422.87	+41.3%	517.54	+15.4%
Profit before tax	24.28	19.20	+26.5%	(27.79)	Turned profit
Net profit for the period	18.52	13.68	+35.4%	(21.23)	Turned profit
EPS, basic (₹)	2.06	1.53	+34.6%	(2.37)	Turned profit
Net margin (%)	3.2	3.6		-4.2

Consolidated

Filed with BSE: 10 Nov 2021, 17:17 IST
Board meeting: 10 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Nov 2021, 17:17 IST
Board meeting: 10 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE